Anne Li September 16th, 2017 email@example.com
Memorial Sloan Kettering’s genomic-sequencing test, called MSK-IMPACT™, analyzes tumors for more than 400 genetic mutations known to play a role in cancer. The goal is to match the tumors with targeted therapies. To get to the heart of what makes these tumors genetically unique, a sample of normal tissue is analyzed for comparison.
See original article at: https://www.mskcc.org/blog/making-impact-msk-s-gene-sequencing-test-reveals-new-findings-about-hereditary-cancer-risk